Call Us Today
Call Us Today
Steve Kherkher - February 26, 2025
For decades, Depo-Provera has been a widely used injectable contraceptive. It often receives praise for its convenience and long-term effectiveness. However, recent lawsuits are emerging linking Depo-Provera to serious health risks, including the development of meningiomas. Meningiomas are slow-growing, potentially dangerous brain tumors. Depo-Provera brain tumor lawsuits have led to the formation of multidistrict litigation (MDL) to consolidate cases and streamline the legal process for affected individuals. If you or a loved one have been diagnosed with a brain tumor after using Depo-Provera, understanding your legal options is crucial.
At Kherkher Garcia, we are committed to helping victims of dangerous or defective drugs pursue justice and secure compensation for their injuries. Below, our harmful drug attorneys provide a guide to the recent Depo-Provera MDL. We also provide information on how we help victims who suffer harm due to dangerous or defective drugs.
On January 30, 2025, the Judicial Panel on Multidistrict Litigation (JPML) conducted a hearing regarding the potential consolidation of Depo-Provera lawsuits. Plaintiffs representing women who developed brain tumors after using the contraceptive shot engaged in legal arguments with Pfizer’s attorneys over the appropriate federal court jurisdiction—California or New York. Attorneys representing affected women continue to push for California, which they believe offers the best legal pathway for pursuing claims against Pfizer. A final ruling from the JPML on the venue is expected by February 7, 2025, providing further clarity on how the litigation will proceed.
A major legal milestone was reached on February 7, 2025, when a multidistrict litigation (MDL) was officially established for individuals who developed meningiomas after using Depo-Provera. Named MDL 3140—IN RE: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation—this consolidation streamlines the legal process for thousands of women pursuing claims against Pfizer. The Judicial Panel on Multidistrict Litigation (JPML) determined that all related lawsuits will proceed in the Northern District of Florida, with Judge M. Casey Rodgers expected to preside over the case. This MDL allows affected individuals to file lawsuits collectively while still maintaining their right to individual compensation.
The multidistrict litigation (MDL) involving Depo-Provera and Pfizer is moving forward. In just two weeks since its formation, key legal actions have already taken place. On February 19, 2025, Judge James V. Ingold issued an order transferring 27 state-level lawsuits to the Northern District of Florida under U.S. District Judge M. Casey Rodgers. Then, on February 21, 2025, Judge Rodgers held a case management conference to address essential matters in the litigation. Given Judge Rodgers’ experience overseeing large-scale product liability cases, including the 3M earplug lawsuits, legal analysts predict an efficient legal process. This could lead to settlement discussions and potential compensation for affected women within the next one to two years.
With a consolidated lawsuit now in place for women affected by Depo-Provera, attorneys are discussing the next phase of the legal battle. Significant developments are expected throughout 2025, including the establishment of a litigation timeline, document exchanges between opposing legal teams, the appointment of lead counsel, and arguments regarding the inclusion of generic Depo-Provera users in the case. Stay informed about the progress of these lawsuits by watching this video.
Depo-Provera, manufactured by Pfizer, is a contraceptive injection containing medroxyprogesterone acetate, a synthetic hormone that prevents pregnancy by suppressing ovulation. While it has been marketed as a safe and effective birth control option, emerging scientific research suggests that prolonged exposure to Depo-Provera may increase the risk of developing meningiomas.
Meningiomas are tumors that form in the meninges, the protective layers surrounding the brain and spinal cord. Although most meningiomas are benign, they can grow and exert pressure on the brain, leading to severe neurological symptoms such as headaches, vision problems, memory loss, and even seizures. Studies have indicated that the prolonged use of progesterone-based contraceptives, such as Depo-Provera, can increase the risk of developing these tumors, particularly in individuals who have used the drug for an extended period.
Women diagnosed with meningiomas after using Depo-Provera are filing brain tumor lawsuits against Pfizer, alleging that the pharmaceutical company failed to adequately warn users about the potential risks. Plaintiffs argue that Pfizer knew or should have known about the link between Depo-Provera and brain tumors but failed to provide proper warnings to consumers and healthcare providers.
These lawsuits seek compensation for:
Due to the growing number of lawsuits, a multidistrict litigation (MDL) has been formed to handle Depo-Provera brain tumor claims more efficiently. On February 7, 2025, the Judicial Panel on Multidistrict Litigation (JPML) approved MDL 3140—IN RE: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation. This consolidation allows similar lawsuits to be grouped together in one court, streamlining pretrial proceedings and ensuring consistency in legal rulings.
The MDL for Depo-Provera lawsuits is taking place in the Northern District of Florida under the supervision of Judge M. Casey Rodgers, an experienced mass tort judge known for handling complex pharmaceutical litigation. The benefits of MDL consolidation include:
While MDL cases are handled collectively for pretrial purposes, each plaintiff retains the right to an individual outcome based on the specifics of their case. This means that compensation amounts may vary depending on the severity of the injuries and the impact on the plaintiff’s life.
Navigating a complex pharmaceutical lawsuit requires the expertise of skilled legal professionals who understand the intricacies of product liability claims. At Kherkher Garcia, we have a proven track record of holding pharmaceutical companies accountable for the harm their products cause. Our dedicated team of attorneys is ready to fight for victims of Depo-Provera-related injuries and ensure they receive the justice and compensation they deserve.
Why Choose Kherkher Garcia?
If you or a loved one developed a brain tumor after using Depo-Provera, it’s crucial to take immediate action. Here are the steps to protect your rights and strengthen your legal claim:
The growing number of lawsuits against Pfizer over Depo-Provera’s alleged link to brain tumors highlights the importance of holding pharmaceutical companies accountable for failing to warn consumers about potential risks. The formation of an MDL is a crucial step in ensuring that victims have a fair and efficient path to justice.
If you or a loved one have been diagnosed with a meningioma after using Depo-Provera, you don’t have to face this battle alone. Kherkher Garcia is here to provide the legal support and advocacy you need to seek compensation for your injuries. Contact us today for a free case evaluation and take the first step toward justice. Call us at 713-333-1030, or submit our website contact form to get started.
Resources:
This page has been written, edited, and reviewed by a team of legal writers following our comprehensive editorial guidelines. This page was approved by attorneys Steve Kherkher and Jesus Garcia Jr., who have more than 50 years of combined legal experience championing the rights of those who have experienced catastrophic injury due to negligence.
Connect with a Kherkher Garcia trial lawyer today to pursue maximum compensation for your injury.
Message Us 
Call Us